nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.167	0.5	CiPCiCtD
Bosutinib—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.167	0.5	CiPCiCtD
Bosutinib—BCR—hematologic cancer	0.0273	0.119	CbGaD
Bosutinib—EIF2AK1—hematologic cancer	0.0273	0.119	CbGaD
Bosutinib—SYK—hematologic cancer	0.0232	0.101	CbGaD
Bosutinib—CDK2—hematologic cancer	0.0189	0.0822	CbGaD
Bosutinib—BTK—hematologic cancer	0.0176	0.0764	CbGaD
Bosutinib—TXK—hematologic cancer	0.0176	0.0764	CbGaD
Bosutinib—ABL2—hematologic cancer	0.0157	0.0681	CbGaD
Bosutinib—LCK—hematologic cancer	0.015	0.065	CbGaD
Bosutinib—MAP2K1—hematologic cancer	0.0133	0.0579	CbGaD
Bosutinib—FGR—hematologic cancer	0.0133	0.0579	CbGaD
Bosutinib—ALK—hematologic cancer	0.00951	0.0413	CbGaD
Bosutinib—CSF1R—hematologic cancer	0.00902	0.0391	CbGaD
Bosutinib—PDGFRB—hematologic cancer	0.00787	0.0341	CbGaD
Bosutinib—ABL1—hematologic cancer	0.00701	0.0304	CbGaD
Bosutinib—BMPR2—Ruxolitinib—hematologic cancer	0.00648	0.0243	CbGbCtD
Bosutinib—CAMK1D—Ruxolitinib—hematologic cancer	0.00648	0.0243	CbGbCtD
Bosutinib—SRC—hematologic cancer	0.00635	0.0275	CbGaD
Bosutinib—PKMYT1—Dasatinib—hematologic cancer	0.00553	0.0207	CbGbCtD
Bosutinib—CSK—Dasatinib—hematologic cancer	0.00553	0.0207	CbGbCtD
Bosutinib—SRMS—Dasatinib—hematologic cancer	0.00553	0.0207	CbGbCtD
Bosutinib—BMX—Dasatinib—hematologic cancer	0.00553	0.0207	CbGbCtD
Bosutinib—WEE2—Dasatinib—hematologic cancer	0.00553	0.0207	CbGbCtD
Bosutinib—SIK3—Dasatinib—hematologic cancer	0.00553	0.0207	CbGbCtD
Bosutinib—MAST1—Ruxolitinib—hematologic cancer	0.00469	0.0176	CbGbCtD
Bosutinib—LRRK2—Ruxolitinib—hematologic cancer	0.00469	0.0176	CbGbCtD
Bosutinib—CAMK2G—Ruxolitinib—hematologic cancer	0.00469	0.0176	CbGbCtD
Bosutinib—ROCK1—Ruxolitinib—hematologic cancer	0.00469	0.0176	CbGbCtD
Bosutinib—EPHB2—Nilotinib—hematologic cancer	0.00452	0.017	CbGbCtD
Bosutinib—EPHB3—Nilotinib—hematologic cancer	0.00452	0.017	CbGbCtD
Bosutinib—HCK—Nilotinib—hematologic cancer	0.00452	0.017	CbGbCtD
Bosutinib—EPHB2—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—EPHB3—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—STK36—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—TXK—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—SIK2—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—LOC102724428—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—HCK—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—SIK1—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—BTK—Dasatinib—hematologic cancer	0.004	0.015	CbGbCtD
Bosutinib—BTK—Mitoxantrone—hematologic cancer	0.00395	0.0148	CbGbCtD
Bosutinib—BMP2K—Ruxolitinib—hematologic cancer	0.00372	0.014	CbGbCtD
Bosutinib—NUAK2—Ruxolitinib—hematologic cancer	0.00372	0.014	CbGbCtD
Bosutinib—MAP3K7—Ruxolitinib—hematologic cancer	0.00372	0.014	CbGbCtD
Bosutinib—EPHB4—Nilotinib—hematologic cancer	0.00359	0.0135	CbGbCtD
Bosutinib—EPHA4—Nilotinib—hematologic cancer	0.00359	0.0135	CbGbCtD
Bosutinib—FRK—Nilotinib—hematologic cancer	0.00359	0.0135	CbGbCtD
Bosutinib—EPHA3—Nilotinib—hematologic cancer	0.00359	0.0135	CbGbCtD
Bosutinib—MAP4K1—Nilotinib—hematologic cancer	0.00359	0.0135	CbGbCtD
Bosutinib—EPHA3—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—FYN—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—FRK—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—EPHB4—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—ERBB3—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—EPHA4—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—STK35—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—TNK2—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—EPHA5—Dasatinib—hematologic cancer	0.00318	0.0119	CbGbCtD
Bosutinib—TAOK3—Ruxolitinib—hematologic cancer	0.00311	0.0117	CbGbCtD
Bosutinib—MAP3K3—Ruxolitinib—hematologic cancer	0.00311	0.0117	CbGbCtD
Bosutinib—EPHA2—Nilotinib—hematologic cancer	0.00301	0.0113	CbGbCtD
Bosutinib—EPHA8—Nilotinib—hematologic cancer	0.00301	0.0113	CbGbCtD
Bosutinib—MAP3K2—Ruxolitinib—hematologic cancer	0.00269	0.0101	CbGbCtD
Bosutinib—IRAK1—Ruxolitinib—hematologic cancer	0.00269	0.0101	CbGbCtD
Bosutinib—YES1—Dasatinib—hematologic cancer	0.00266	0.00997	CbGbCtD
Bosutinib—EPHA8—Dasatinib—hematologic cancer	0.00266	0.00997	CbGbCtD
Bosutinib—MAP4K5—Dasatinib—hematologic cancer	0.00266	0.00997	CbGbCtD
Bosutinib—MAP3K3—Dasatinib—hematologic cancer	0.00266	0.00997	CbGbCtD
Bosutinib—EPHA2—Dasatinib—hematologic cancer	0.00266	0.00997	CbGbCtD
Bosutinib—FGR—Nilotinib—hematologic cancer	0.0026	0.00975	CbGbCtD
Bosutinib—HIPK4—Imatinib—hematologic cancer	0.00253	0.00948	CbGbCtD
Bosutinib—BLK—Nilotinib—hematologic cancer	0.0023	0.00862	CbGbCtD
Bosutinib—LYN—Nilotinib—hematologic cancer	0.0023	0.00862	CbGbCtD
Bosutinib—FGR—Dasatinib—hematologic cancer	0.0023	0.00861	CbGbCtD
Bosutinib—MAP3K2—Dasatinib—hematologic cancer	0.0023	0.00861	CbGbCtD
Bosutinib—CSF1R—Imatinib—hematologic cancer	0.00227	0.00852	CbGbCtD
Bosutinib—ABL2—Imatinib—hematologic cancer	0.00227	0.00852	CbGbCtD
Bosutinib—LCK—Imatinib—hematologic cancer	0.00207	0.00775	CbGbCtD
Bosutinib—PDGFRB—Imatinib—hematologic cancer	0.00207	0.00775	CbGbCtD
Bosutinib—ABL2—Nilotinib—hematologic cancer	0.00206	0.00774	CbGbCtD
Bosutinib—CSF1R—Nilotinib—hematologic cancer	0.00206	0.00774	CbGbCtD
Bosutinib—BLK—Dasatinib—hematologic cancer	0.00203	0.00762	CbGbCtD
Bosutinib—SRC—Dasatinib—hematologic cancer	0.00203	0.00762	CbGbCtD
Bosutinib—LYN—Dasatinib—hematologic cancer	0.00203	0.00762	CbGbCtD
Bosutinib—MAP2K5—Nilotinib—hematologic cancer	0.00188	0.00705	CbGbCtD
Bosutinib—LCK—Nilotinib—hematologic cancer	0.00188	0.00705	CbGbCtD
Bosutinib—PDGFRB—Nilotinib—hematologic cancer	0.00188	0.00705	CbGbCtD
Bosutinib—CSF1R—Dasatinib—hematologic cancer	0.00182	0.00684	CbGbCtD
Bosutinib—ABL2—Dasatinib—hematologic cancer	0.00182	0.00684	CbGbCtD
Bosutinib—MAP3K19—Ruxolitinib—hematologic cancer	0.00179	0.00671	CbGbCtD
Bosutinib—MAP2K5—Dasatinib—hematologic cancer	0.00166	0.00623	CbGbCtD
Bosutinib—LCK—Dasatinib—hematologic cancer	0.00166	0.00623	CbGbCtD
Bosutinib—PDGFRB—Dasatinib—hematologic cancer	0.00166	0.00623	CbGbCtD
Bosutinib—ABL1—Imatinib—hematologic cancer	0.00164	0.00616	CbGbCtD
Bosutinib—MAP3K19—Dasatinib—hematologic cancer	0.00153	0.00572	CbGbCtD
Bosutinib—ABL1—Nilotinib—hematologic cancer	0.00149	0.0056	CbGbCtD
Bosutinib—ABL1—Dasatinib—hematologic cancer	0.00132	0.00495	CbGbCtD
Bosutinib—ABCB1—hematologic cancer	0.0013	0.00563	CbGaD
Bosutinib—ABCB1—Lenalidomide—hematologic cancer	0.000301	0.00113	CbGbCtD
Bosutinib—Vandetanib—FLT3—hematologic cancer	0.000247	0.161	CrCbGaD
Bosutinib—Vandetanib—ABL2—hematologic cancer	0.00022	0.144	CrCbGaD
Bosutinib—Vandetanib—LCK—hematologic cancer	0.00021	0.137	CrCbGaD
Bosutinib—Vandetanib—FGR—hematologic cancer	0.000187	0.122	CrCbGaD
Bosutinib—CYP3A4—Bexarotene—hematologic cancer	0.00018	0.000677	CbGbCtD
Bosutinib—ABCB1—Daunorubicin—hematologic cancer	0.000177	0.000662	CbGbCtD
Bosutinib—ABCB1—Alitretinoin—hematologic cancer	0.000173	0.000649	CbGbCtD
Bosutinib—CYP3A4—Lomustine—hematologic cancer	0.000168	0.000629	CbGbCtD
Bosutinib—CYP3A4—Busulfan—hematologic cancer	0.000168	0.000629	CbGbCtD
Bosutinib—Vandetanib—RET—hematologic cancer	0.000159	0.104	CrCbGaD
Bosutinib—CYP3A4—Thiotepa—hematologic cancer	0.000149	0.000561	CbGbCtD
Bosutinib—ABCB1—Imatinib—hematologic cancer	0.000135	0.000507	CbGbCtD
Bosutinib—ABCB1—Nilotinib—hematologic cancer	0.000123	0.000461	CbGbCtD
Bosutinib—ABCB1—Vinorelbine—hematologic cancer	0.000122	0.000457	CbGbCtD
Bosutinib—CYP3A4—Methoxsalen—hematologic cancer	0.000116	0.000436	CbGbCtD
Bosutinib—CYP3A4—Bortezomib—hematologic cancer	0.000111	0.000415	CbGbCtD
Bosutinib—Vandetanib—PDGFRB—hematologic cancer	0.00011	0.072	CrCbGaD
Bosutinib—ABCB1—Dasatinib—hematologic cancer	0.000109	0.000407	CbGbCtD
Bosutinib—ABCB1—Mitoxantrone—hematologic cancer	0.000107	0.000402	CbGbCtD
Bosutinib—CYP3A4—Daunorubicin—hematologic cancer	0.000106	0.000397	CbGbCtD
Bosutinib—Vandetanib—ABL1—hematologic cancer	9.83e-05	0.0642	CrCbGaD
Bosutinib—ABCB1—Betamethasone—hematologic cancer	9.56e-05	0.000359	CbGbCtD
Bosutinib—ABCB1—Gemcitabine—hematologic cancer	9.47e-05	0.000356	CbGbCtD
Bosutinib—ABCB1—Prednisolone—hematologic cancer	9.43e-05	0.000354	CbGbCtD
Bosutinib—CYP3A4—Cytarabine—hematologic cancer	9.33e-05	0.00035	CbGbCtD
Bosutinib—CYP3A4—Teniposide—hematologic cancer	9.19e-05	0.000345	CbGbCtD
Bosutinib—ABCB1—Prednisone—hematologic cancer	8.91e-05	0.000334	CbGbCtD
Bosutinib—Vandetanib—SRC—hematologic cancer	8.9e-05	0.0581	CrCbGaD
Bosutinib—CYP3A4—Ifosfamide—hematologic cancer	8.48e-05	0.000318	CbGbCtD
Bosutinib—ABCB1—Irinotecan—hematologic cancer	8.45e-05	0.000317	CbGbCtD
Bosutinib—CYP3A4—Imatinib—hematologic cancer	8.1e-05	0.000304	CbGbCtD
Bosutinib—CYP3A4—Ruxolitinib—hematologic cancer	7.63e-05	0.000286	CbGbCtD
Bosutinib—ABCB1—Vinblastine—hematologic cancer	7.51e-05	0.000282	CbGbCtD
Bosutinib—ABCB1—Vincristine—hematologic cancer	7.38e-05	0.000277	CbGbCtD
Bosutinib—CYP3A4—Nilotinib—hematologic cancer	7.36e-05	0.000276	CbGbCtD
Bosutinib—CYP3A4—Vinorelbine—hematologic cancer	7.3e-05	0.000274	CbGbCtD
Bosutinib—Vandetanib—VEGFA—hematologic cancer	7.09e-05	0.0463	CrCbGaD
Bosutinib—ABCB1—Cisplatin—hematologic cancer	6.88e-05	0.000258	CbGbCtD
Bosutinib—ABCB1—Etoposide—hematologic cancer	6.76e-05	0.000254	CbGbCtD
Bosutinib—CYP3A4—Triamcinolone—hematologic cancer	6.68e-05	0.000251	CbGbCtD
Bosutinib—STK36—lung—hematologic cancer	6.61e-05	0.00179	CbGeAlD
Bosutinib—EPHB3—lung—hematologic cancer	6.61e-05	0.00179	CbGeAlD
Bosutinib—CAMK2G—bone marrow—hematologic cancer	6.59e-05	0.00178	CbGeAlD
Bosutinib—BMP2K—bone marrow—hematologic cancer	6.59e-05	0.00178	CbGeAlD
Bosutinib—VRK2—lymph node—hematologic cancer	6.58e-05	0.00178	CbGeAlD
Bosutinib—FES—lymph node—hematologic cancer	6.58e-05	0.00178	CbGeAlD
Bosutinib—PTK2B—blood—hematologic cancer	6.57e-05	0.00177	CbGeAlD
Bosutinib—ERBB4—testis—hematologic cancer	6.56e-05	0.00177	CbGeAlD
Bosutinib—STK3—testis—hematologic cancer	6.56e-05	0.00177	CbGeAlD
Bosutinib—MERTK—lung—hematologic cancer	6.54e-05	0.00177	CbGeAlD
Bosutinib—LRRK2—bone marrow—hematologic cancer	6.53e-05	0.00176	CbGeAlD
Bosutinib—CYP3A4—Dasatinib—hematologic cancer	6.51e-05	0.000244	CbGbCtD
Bosutinib—ROCK1—testis—hematologic cancer	6.48e-05	0.00175	CbGeAlD
Bosutinib—CSNK1E—blood—hematologic cancer	6.47e-05	0.00175	CbGeAlD
Bosutinib—SYK—lymph node—hematologic cancer	6.45e-05	0.00174	CbGeAlD
Bosutinib—TNIK—lymph node—hematologic cancer	6.45e-05	0.00174	CbGeAlD
Bosutinib—CYP3A4—Mitoxantrone—hematologic cancer	6.43e-05	0.000241	CbGbCtD
Bosutinib—MAP4K4—lung—hematologic cancer	6.42e-05	0.00173	CbGeAlD
Bosutinib—CDK2—lymph node—hematologic cancer	6.39e-05	0.00173	CbGeAlD
Bosutinib—NUAK2—lung—hematologic cancer	6.37e-05	0.00172	CbGeAlD
Bosutinib—BCR—lung—hematologic cancer	6.37e-05	0.00172	CbGeAlD
Bosutinib—SIK1—blood—hematologic cancer	6.37e-05	0.00172	CbGeAlD
Bosutinib—IRAK4—blood—hematologic cancer	6.37e-05	0.00172	CbGeAlD
Bosutinib—PTK2B—bone marrow—hematologic cancer	6.36e-05	0.00172	CbGeAlD
Bosutinib—CSF1R—hematopoietic system—hematologic cancer	6.35e-05	0.00171	CbGeAlD
Bosutinib—STK26—lymph node—hematologic cancer	6.33e-05	0.00171	CbGeAlD
Bosutinib—MAP3K12—lung—hematologic cancer	6.33e-05	0.00171	CbGeAlD
Bosutinib—EPHA4—blood—hematologic cancer	6.3e-05	0.0017	CbGeAlD
Bosutinib—BMPR2—testis—hematologic cancer	6.29e-05	0.0017	CbGeAlD
Bosutinib—EPHB3—testis—hematologic cancer	6.24e-05	0.00169	CbGeAlD
Bosutinib—STK36—testis—hematologic cancer	6.24e-05	0.00169	CbGeAlD
Bosutinib—MAP2K2—blood—hematologic cancer	6.22e-05	0.00168	CbGeAlD
Bosutinib—ULK3—blood—hematologic cancer	6.22e-05	0.00168	CbGeAlD
Bosutinib—STK35—lung—hematologic cancer	6.2e-05	0.00167	CbGeAlD
Bosutinib—MAP2K1—lung—hematologic cancer	6.2e-05	0.00167	CbGeAlD
Bosutinib—MAP3K2—blood—hematologic cancer	6.18e-05	0.00167	CbGeAlD
Bosutinib—MERTK—testis—hematologic cancer	6.17e-05	0.00167	CbGeAlD
Bosutinib—IRAK4—bone marrow—hematologic cancer	6.16e-05	0.00166	CbGeAlD
Bosutinib—SIK1—bone marrow—hematologic cancer	6.16e-05	0.00166	CbGeAlD
Bosutinib—CSK—lung—hematologic cancer	6.16e-05	0.00166	CbGeAlD
Bosutinib—MAP3K7—blood—hematologic cancer	6.12e-05	0.00165	CbGeAlD
Bosutinib—CSNK1A1—lung—hematologic cancer	6.12e-05	0.00165	CbGeAlD
Bosutinib—CHEK2—lymph node—hematologic cancer	6.12e-05	0.00165	CbGeAlD
Bosutinib—HCK—lung—hematologic cancer	6.08e-05	0.00164	CbGeAlD
Bosutinib—CLK1—lung—hematologic cancer	6.08e-05	0.00164	CbGeAlD
Bosutinib—DMPK—lymph node—hematologic cancer	6.07e-05	0.00164	CbGeAlD
Bosutinib—WEE1—lymph node—hematologic cancer	6.07e-05	0.00164	CbGeAlD
Bosutinib—MAP4K4—testis—hematologic cancer	6.06e-05	0.00164	CbGeAlD
Bosutinib—PTK2—blood—hematologic cancer	6.05e-05	0.00163	CbGeAlD
Bosutinib—TBK1—blood—hematologic cancer	6.05e-05	0.00163	CbGeAlD
Bosutinib—MAP4K5—gonad—hematologic cancer	6.05e-05	0.00163	CbGeAlD
Bosutinib—MAP3K3—gonad—hematologic cancer	6.05e-05	0.00163	CbGeAlD
Bosutinib—ABL2—lung—hematologic cancer	6.04e-05	0.00163	CbGeAlD
Bosutinib—ULK3—bone marrow—hematologic cancer	6.02e-05	0.00163	CbGeAlD
Bosutinib—MAP2K2—bone marrow—hematologic cancer	6.02e-05	0.00163	CbGeAlD
Bosutinib—BCR—testis—hematologic cancer	6.01e-05	0.00162	CbGeAlD
Bosutinib—NUAK2—testis—hematologic cancer	6.01e-05	0.00162	CbGeAlD
Bosutinib—MAP3K2—bone marrow—hematologic cancer	5.98e-05	0.00161	CbGeAlD
Bosutinib—MAP3K12—testis—hematologic cancer	5.97e-05	0.00161	CbGeAlD
Bosutinib—BMP2K—lung—hematologic cancer	5.97e-05	0.00161	CbGeAlD
Bosutinib—CAMK2G—lung—hematologic cancer	5.97e-05	0.00161	CbGeAlD
Bosutinib—IRAK1—blood—hematologic cancer	5.93e-05	0.0016	CbGeAlD
Bosutinib—MAP3K7—bone marrow—hematologic cancer	5.92e-05	0.0016	CbGeAlD
Bosutinib—LRRK2—lung—hematologic cancer	5.91e-05	0.0016	CbGeAlD
Bosutinib—EGFR—lung—hematologic cancer	5.9e-05	0.00159	CbGeAlD
Bosutinib—TBK1—bone marrow—hematologic cancer	5.86e-05	0.00158	CbGeAlD
Bosutinib—MAP2K1—testis—hematologic cancer	5.85e-05	0.00158	CbGeAlD
Bosutinib—STK35—testis—hematologic cancer	5.85e-05	0.00158	CbGeAlD
Bosutinib—RPS6KB1—blood—hematologic cancer	5.82e-05	0.00157	CbGeAlD
Bosutinib—CSK—testis—hematologic cancer	5.81e-05	0.00157	CbGeAlD
Bosutinib—STK25—lymph node—hematologic cancer	5.79e-05	0.00156	CbGeAlD
Bosutinib—FGR—blood—hematologic cancer	5.79e-05	0.00156	CbGeAlD
Bosutinib—LCK—blood—hematologic cancer	5.79e-05	0.00156	CbGeAlD
Bosutinib—CSNK1A1—testis—hematologic cancer	5.77e-05	0.00156	CbGeAlD
Bosutinib—PTK2B—lung—hematologic cancer	5.76e-05	0.00156	CbGeAlD
Bosutinib—EPHA3—lymph node—hematologic cancer	5.75e-05	0.00155	CbGeAlD
Bosutinib—IRAK1—bone marrow—hematologic cancer	5.74e-05	0.00155	CbGeAlD
Bosutinib—HCK—testis—hematologic cancer	5.74e-05	0.00155	CbGeAlD
Bosutinib—CLK1—testis—hematologic cancer	5.74e-05	0.00155	CbGeAlD
Bosutinib—CYP3A4—Betamethasone—hematologic cancer	5.73e-05	0.000215	CbGbCtD
Bosutinib—ABL2—testis—hematologic cancer	5.7e-05	0.00154	CbGeAlD
Bosutinib—CSNK1E—lung—hematologic cancer	5.67e-05	0.00153	CbGeAlD
Bosutinib—CYP3A4—Prednisolone—hematologic cancer	5.65e-05	0.000212	CbGbCtD
Bosutinib—RPS6KB1—bone marrow—hematologic cancer	5.63e-05	0.00152	CbGeAlD
Bosutinib—PLK2—lymph node—hematologic cancer	5.63e-05	0.00152	CbGeAlD
Bosutinib—CAMK2G—testis—hematologic cancer	5.63e-05	0.00152	CbGeAlD
Bosutinib—BMP2K—testis—hematologic cancer	5.63e-05	0.00152	CbGeAlD
Bosutinib—PDGFRB—hematopoietic system—hematologic cancer	5.63e-05	0.00152	CbGeAlD
Bosutinib—FGR—bone marrow—hematologic cancer	5.6e-05	0.00151	CbGeAlD
Bosutinib—LCK—bone marrow—hematologic cancer	5.6e-05	0.00151	CbGeAlD
Bosutinib—SIK3—lymph node—hematologic cancer	5.59e-05	0.00151	CbGeAlD
Bosutinib—YES1—gonad—hematologic cancer	5.59e-05	0.00151	CbGeAlD
Bosutinib—SIK1—lung—hematologic cancer	5.58e-05	0.00151	CbGeAlD
Bosutinib—IRAK4—lung—hematologic cancer	5.58e-05	0.00151	CbGeAlD
Bosutinib—LRRK2—testis—hematologic cancer	5.58e-05	0.00151	CbGeAlD
Bosutinib—EGFR—testis—hematologic cancer	5.56e-05	0.0015	CbGeAlD
Bosutinib—ABCB1—Dexamethasone—hematologic cancer	5.56e-05	0.000209	CbGbCtD
Bosutinib—SLK—blood—hematologic cancer	5.55e-05	0.0015	CbGeAlD
Bosutinib—STK10—gonad—hematologic cancer	5.54e-05	0.00149	CbGeAlD
Bosutinib—EPHA4—lung—hematologic cancer	5.52e-05	0.00149	CbGeAlD
Bosutinib—EPHB4—blood—hematologic cancer	5.51e-05	0.00149	CbGeAlD
Bosutinib—ERBB3—lung—hematologic cancer	5.47e-05	0.00148	CbGeAlD
Bosutinib—ULK3—lung—hematologic cancer	5.46e-05	0.00147	CbGeAlD
Bosutinib—MAP2K2—lung—hematologic cancer	5.46e-05	0.00147	CbGeAlD
Bosutinib—PTK2B—testis—hematologic cancer	5.44e-05	0.00147	CbGeAlD
Bosutinib—MAP3K2—lung—hematologic cancer	5.42e-05	0.00146	CbGeAlD
Bosutinib—EPHA2—blood—hematologic cancer	5.4e-05	0.00146	CbGeAlD
Bosutinib—FYN—blood—hematologic cancer	5.39e-05	0.00146	CbGeAlD
Bosutinib—STK4—lymph node—hematologic cancer	5.38e-05	0.00145	CbGeAlD
Bosutinib—SRC—gonad—hematologic cancer	5.38e-05	0.00145	CbGeAlD
Bosutinib—SLK—bone marrow—hematologic cancer	5.37e-05	0.00145	CbGeAlD
Bosutinib—MAP3K7—lung—hematologic cancer	5.37e-05	0.00145	CbGeAlD
Bosutinib—CSNK1E—testis—hematologic cancer	5.35e-05	0.00144	CbGeAlD
Bosutinib—CYP3A4—Prednisone—hematologic cancer	5.34e-05	0.0002	CbGbCtD
Bosutinib—EPHB4—bone marrow—hematologic cancer	5.33e-05	0.00144	CbGeAlD
Bosutinib—CAMK1D—lymph node—hematologic cancer	5.32e-05	0.00144	CbGeAlD
Bosutinib—TBK1—lung—hematologic cancer	5.31e-05	0.00143	CbGeAlD
Bosutinib—PTK2—lung—hematologic cancer	5.31e-05	0.00143	CbGeAlD
Bosutinib—MAP3K3—blood—hematologic cancer	5.27e-05	0.00142	CbGeAlD
Bosutinib—MAP4K5—blood—hematologic cancer	5.27e-05	0.00142	CbGeAlD
Bosutinib—SIK1—testis—hematologic cancer	5.27e-05	0.00142	CbGeAlD
Bosutinib—IRAK4—testis—hematologic cancer	5.27e-05	0.00142	CbGeAlD
Bosutinib—STK24—lymph node—hematologic cancer	5.26e-05	0.00142	CbGeAlD
Bosutinib—FYN—bone marrow—hematologic cancer	5.22e-05	0.00141	CbGeAlD
Bosutinib—EPHA4—testis—hematologic cancer	5.21e-05	0.00141	CbGeAlD
Bosutinib—IRAK1—lung—hematologic cancer	5.2e-05	0.0014	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Idarubicin—hematologic cancer	5.18e-05	0.045	CbGdCrCtD
Bosutinib—ERBB3—testis—hematologic cancer	5.16e-05	0.00139	CbGeAlD
Bosutinib—ULK3—testis—hematologic cancer	5.15e-05	0.00139	CbGeAlD
Bosutinib—MAP2K2—testis—hematologic cancer	5.15e-05	0.00139	CbGeAlD
Bosutinib—MAP3K2—testis—hematologic cancer	5.11e-05	0.00138	CbGeAlD
Bosutinib—RPS6KB1—lung—hematologic cancer	5.1e-05	0.00138	CbGeAlD
Bosutinib—MAP4K5—bone marrow—hematologic cancer	5.1e-05	0.00138	CbGeAlD
Bosutinib—MAP3K3—bone marrow—hematologic cancer	5.1e-05	0.00138	CbGeAlD
Bosutinib—ALK—lymph node—hematologic cancer	5.09e-05	0.00137	CbGeAlD
Bosutinib—FER—lymph node—hematologic cancer	5.09e-05	0.00137	CbGeAlD
Bosutinib—LCK—lung—hematologic cancer	5.07e-05	0.00137	CbGeAlD
Bosutinib—FGR—lung—hematologic cancer	5.07e-05	0.00137	CbGeAlD
Bosutinib—MAP3K7—testis—hematologic cancer	5.06e-05	0.00137	CbGeAlD
Bosutinib—CYP3A4—Irinotecan—hematologic cancer	5.06e-05	0.00019	CbGbCtD
Bosutinib—AXL—lung—hematologic cancer	5.05e-05	0.00136	CbGeAlD
Bosutinib—ABL1—hematopoietic system—hematologic cancer	5.02e-05	0.00135	CbGeAlD
Bosutinib—PTK2—testis—hematologic cancer	5.01e-05	0.00135	CbGeAlD
Bosutinib—TBK1—testis—hematologic cancer	5.01e-05	0.00135	CbGeAlD
Bosutinib—MAP4K1—lymph node—hematologic cancer	4.99e-05	0.00135	CbGeAlD
Bosutinib—BTK—lymph node—hematologic cancer	4.96e-05	0.00134	CbGeAlD
Bosutinib—IRAK1—testis—hematologic cancer	4.91e-05	0.00133	CbGeAlD
Bosutinib—TNK2—lymph node—hematologic cancer	4.89e-05	0.00132	CbGeAlD
Bosutinib—YES1—blood—hematologic cancer	4.87e-05	0.00131	CbGeAlD
Bosutinib—SLK—lung—hematologic cancer	4.86e-05	0.00131	CbGeAlD
Bosutinib—EPHB4—lung—hematologic cancer	4.83e-05	0.0013	CbGeAlD
Bosutinib—CSF1R—gonad—hematologic cancer	4.83e-05	0.0013	CbGeAlD
Bosutinib—STK10—blood—hematologic cancer	4.82e-05	0.0013	CbGeAlD
Bosutinib—MAP4K2—lymph node—hematologic cancer	4.82e-05	0.0013	CbGeAlD
Bosutinib—RPS6KB1—testis—hematologic cancer	4.82e-05	0.0013	CbGeAlD
Bosutinib—TAOK3—blood—hematologic cancer	4.81e-05	0.0013	CbGeAlD
Bosutinib—LCK—testis—hematologic cancer	4.79e-05	0.00129	CbGeAlD
Bosutinib—FGR—testis—hematologic cancer	4.79e-05	0.00129	CbGeAlD
Bosutinib—AXL—testis—hematologic cancer	4.77e-05	0.00129	CbGeAlD
Bosutinib—STK3—lymph node—hematologic cancer	4.76e-05	0.00128	CbGeAlD
Bosutinib—EPHA2—lung—hematologic cancer	4.74e-05	0.00128	CbGeAlD
Bosutinib—FYN—lung—hematologic cancer	4.73e-05	0.00128	CbGeAlD
Bosutinib—YES1—bone marrow—hematologic cancer	4.71e-05	0.00127	CbGeAlD
Bosutinib—SRC—blood—hematologic cancer	4.68e-05	0.00126	CbGeAlD
Bosutinib—STK10—bone marrow—hematologic cancer	4.67e-05	0.00126	CbGeAlD
Bosutinib—TAOK3—bone marrow—hematologic cancer	4.65e-05	0.00126	CbGeAlD
Bosutinib—MAP4K5—lung—hematologic cancer	4.62e-05	0.00125	CbGeAlD
Bosutinib—MAP3K3—lung—hematologic cancer	4.62e-05	0.00125	CbGeAlD
Bosutinib—ABCB1—Doxorubicin—hematologic cancer	4.61e-05	0.000173	CbGbCtD
Bosutinib—SLK—testis—hematologic cancer	4.59e-05	0.00124	CbGeAlD
Bosutinib—CHEK2—Nilotinib—Imatinib—hematologic cancer	4.56e-05	0.0396	CbGdCrCtD
Bosutinib—BMPR2—lymph node—hematologic cancer	4.56e-05	0.00123	CbGeAlD
Bosutinib—EPHB4—testis—hematologic cancer	4.56e-05	0.00123	CbGeAlD
Bosutinib—STK36—lymph node—hematologic cancer	4.52e-05	0.00122	CbGeAlD
Bosutinib—EPHB3—lymph node—hematologic cancer	4.52e-05	0.00122	CbGeAlD
Bosutinib—CYP3A4—Vinblastine—hematologic cancer	4.5e-05	0.000169	CbGbCtD
Bosutinib—MERTK—lymph node—hematologic cancer	4.47e-05	0.00121	CbGeAlD
Bosutinib—EPHA2—testis—hematologic cancer	4.47e-05	0.00121	CbGeAlD
Bosutinib—ABCB1—Methotrexate—hematologic cancer	4.47e-05	0.000168	CbGbCtD
Bosutinib—FYN—testis—hematologic cancer	4.46e-05	0.0012	CbGeAlD
Bosutinib—CYP3A4—Vincristine—hematologic cancer	4.42e-05	0.000166	CbGbCtD
Bosutinib—MAP4K4—lymph node—hematologic cancer	4.39e-05	0.00119	CbGeAlD
Bosutinib—Vandetanib—ABCG2—hematologic cancer	4.37e-05	0.0285	CrCbGaD
Bosutinib—MAP3K3—testis—hematologic cancer	4.36e-05	0.00118	CbGeAlD
Bosutinib—MAP4K5—testis—hematologic cancer	4.36e-05	0.00118	CbGeAlD
Bosutinib—BCR—lymph node—hematologic cancer	4.36e-05	0.00118	CbGeAlD
Bosutinib—NUAK2—lymph node—hematologic cancer	4.36e-05	0.00118	CbGeAlD
Bosutinib—MAP3K12—lymph node—hematologic cancer	4.33e-05	0.00117	CbGeAlD
Bosutinib—MAP2K5—blood—hematologic cancer	4.31e-05	0.00116	CbGeAlD
Bosutinib—PDGFRB—gonad—hematologic cancer	4.28e-05	0.00116	CbGeAlD
Bosutinib—YES1—lung—hematologic cancer	4.27e-05	0.00115	CbGeAlD
Bosutinib—STK35—lymph node—hematologic cancer	4.24e-05	0.00114	CbGeAlD
Bosutinib—MAP2K1—lymph node—hematologic cancer	4.24e-05	0.00114	CbGeAlD
Bosutinib—STK10—lung—hematologic cancer	4.23e-05	0.00114	CbGeAlD
Bosutinib—TAOK3—lung—hematologic cancer	4.21e-05	0.00114	CbGeAlD
Bosutinib—CSK—lymph node—hematologic cancer	4.21e-05	0.00114	CbGeAlD
Bosutinib—CSF1R—blood—hematologic cancer	4.2e-05	0.00114	CbGeAlD
Bosutinib—CSNK1A1—lymph node—hematologic cancer	4.18e-05	0.00113	CbGeAlD
Bosutinib—HCK—lymph node—hematologic cancer	4.16e-05	0.00112	CbGeAlD
Bosutinib—CLK1—lymph node—hematologic cancer	4.16e-05	0.00112	CbGeAlD
Bosutinib—Gefitinib—ABCG2—hematologic cancer	4.15e-05	0.0271	CrCbGaD
Bosutinib—ABL2—lymph node—hematologic cancer	4.13e-05	0.00112	CbGeAlD
Bosutinib—SRC—lung—hematologic cancer	4.11e-05	0.00111	CbGeAlD
Bosutinib—BMP2K—lymph node—hematologic cancer	4.08e-05	0.0011	CbGeAlD
Bosutinib—CAMK2G—lymph node—hematologic cancer	4.08e-05	0.0011	CbGeAlD
Bosutinib—CSF1R—bone marrow—hematologic cancer	4.07e-05	0.0011	CbGeAlD
Bosutinib—STK24—Teniposide—Etoposide—hematologic cancer	4.07e-05	0.0353	CbGdCrCtD
Bosutinib—CYP3A4—Etoposide—hematologic cancer	4.05e-05	0.000152	CbGbCtD
Bosutinib—LRRK2—lymph node—hematologic cancer	4.04e-05	0.00109	CbGeAlD
Bosutinib—EGFR—lymph node—hematologic cancer	4.03e-05	0.00109	CbGeAlD
Bosutinib—YES1—testis—hematologic cancer	4.03e-05	0.00109	CbGeAlD
Bosutinib—STK10—testis—hematologic cancer	3.99e-05	0.00108	CbGeAlD
Bosutinib—TAOK3—testis—hematologic cancer	3.98e-05	0.00107	CbGeAlD
Bosutinib—PTK2B—lymph node—hematologic cancer	3.94e-05	0.00106	CbGeAlD
Bosutinib—CSNK1E—lymph node—hematologic cancer	3.88e-05	0.00105	CbGeAlD
Bosutinib—SRC—testis—hematologic cancer	3.87e-05	0.00105	CbGeAlD
Bosutinib—SIK1—lymph node—hematologic cancer	3.82e-05	0.00103	CbGeAlD
Bosutinib—IRAK4—lymph node—hematologic cancer	3.82e-05	0.00103	CbGeAlD
Bosutinib—ABL1—gonad—hematologic cancer	3.81e-05	0.00103	CbGeAlD
Bosutinib—EPHA4—lymph node—hematologic cancer	3.78e-05	0.00102	CbGeAlD
Bosutinib—MAP2K5—lung—hematologic cancer	3.78e-05	0.00102	CbGeAlD
Bosutinib—ERBB3—lymph node—hematologic cancer	3.74e-05	0.00101	CbGeAlD
Bosutinib—MAP2K2—lymph node—hematologic cancer	3.73e-05	0.00101	CbGeAlD
Bosutinib—ULK3—lymph node—hematologic cancer	3.73e-05	0.00101	CbGeAlD
Bosutinib—PDGFRB—blood—hematologic cancer	3.73e-05	0.00101	CbGeAlD
Bosutinib—MAP3K2—lymph node—hematologic cancer	3.71e-05	0.001	CbGeAlD
Bosutinib—CSF1R—lung—hematologic cancer	3.69e-05	0.000995	CbGeAlD
Bosutinib—MAP3K7—lymph node—hematologic cancer	3.67e-05	0.000991	CbGeAlD
Bosutinib—TBK1—lymph node—hematologic cancer	3.63e-05	0.00098	CbGeAlD
Bosutinib—PTK2—lymph node—hematologic cancer	3.63e-05	0.00098	CbGeAlD
Bosutinib—PDGFRB—bone marrow—hematologic cancer	3.61e-05	0.000974	CbGeAlD
Bosutinib—MAP2K5—testis—hematologic cancer	3.56e-05	0.000962	CbGeAlD
Bosutinib—IRAK1—lymph node—hematologic cancer	3.56e-05	0.000961	CbGeAlD
Bosutinib—CHEK2—Ponatinib—Nilotinib—hematologic cancer	3.52e-05	0.0306	CbGdCrCtD
Bosutinib—RPS6KB1—lymph node—hematologic cancer	3.49e-05	0.000943	CbGeAlD
Bosutinib—CSF1R—testis—hematologic cancer	3.48e-05	0.000939	CbGeAlD
Bosutinib—LCK—lymph node—hematologic cancer	3.47e-05	0.000937	CbGeAlD
Bosutinib—FGR—lymph node—hematologic cancer	3.47e-05	0.000937	CbGeAlD
Bosutinib—AXL—lymph node—hematologic cancer	3.46e-05	0.000933	CbGeAlD
Bosutinib—CYP3A4—Dexamethasone—hematologic cancer	3.33e-05	0.000125	CbGbCtD
Bosutinib—SLK—lymph node—hematologic cancer	3.33e-05	0.000898	CbGeAlD
Bosutinib—ABL1—blood—hematologic cancer	3.32e-05	0.000897	CbGeAlD
Bosutinib—EPHB4—lymph node—hematologic cancer	3.3e-05	0.000892	CbGeAlD
Bosutinib—PDGFRB—lung—hematologic cancer	3.27e-05	0.000883	CbGeAlD
Bosutinib—EPHA2—lymph node—hematologic cancer	3.24e-05	0.000875	CbGeAlD
Bosutinib—FYN—lymph node—hematologic cancer	3.23e-05	0.000873	CbGeAlD
Bosutinib—ABL1—bone marrow—hematologic cancer	3.22e-05	0.000868	CbGeAlD
Bosutinib—CDK2—Vinblastine—Vinorelbine—hematologic cancer	3.2e-05	0.0278	CbGdCrCtD
Bosutinib—MAP3K3—lymph node—hematologic cancer	3.16e-05	0.000853	CbGeAlD
Bosutinib—MAP4K5—lymph node—hematologic cancer	3.16e-05	0.000853	CbGeAlD
Bosutinib—PDGFRB—testis—hematologic cancer	3.08e-05	0.000833	CbGeAlD
Bosutinib—CAMK2G—Azacitidine—Pentostatin—hematologic cancer	2.98e-05	0.0258	CbGdCrCtD
Bosutinib—YES1—lymph node—hematologic cancer	2.92e-05	0.000788	CbGeAlD
Bosutinib—ABL1—lung—hematologic cancer	2.91e-05	0.000787	CbGeAlD
Bosutinib—STK10—lymph node—hematologic cancer	2.89e-05	0.000781	CbGeAlD
Bosutinib—TAOK3—lymph node—hematologic cancer	2.88e-05	0.000778	CbGeAlD
Bosutinib—ERBB3—Podofilox—Teniposide—hematologic cancer	2.84e-05	0.0246	CbGdCrCtD
Bosutinib—SRC—lymph node—hematologic cancer	2.81e-05	0.000758	CbGeAlD
Bosutinib—CYP3A4—Doxorubicin—hematologic cancer	2.76e-05	0.000104	CbGbCtD
Bosutinib—ABL1—testis—hematologic cancer	2.75e-05	0.000742	CbGeAlD
Bosutinib—CHEK2—Ponatinib—Imatinib—hematologic cancer	2.67e-05	0.0232	CbGdCrCtD
Bosutinib—CAMK2G—Azacitidine—Clofarabine—hematologic cancer	2.65e-05	0.023	CbGdCrCtD
Bosutinib—CASK—Teniposide—Etoposide—hematologic cancer	2.62e-05	0.0227	CbGdCrCtD
Bosutinib—MAP2K5—lymph node—hematologic cancer	2.58e-05	0.000697	CbGeAlD
Bosutinib—CDK2—Vinblastine—Vincristine—hematologic cancer	2.56e-05	0.0222	CbGdCrCtD
Bosutinib—CSF1R—lymph node—hematologic cancer	2.52e-05	0.000681	CbGeAlD
Bosutinib—CAMK2G—Azacitidine—Nelarabine—hematologic cancer	2.5e-05	0.0217	CbGdCrCtD
Bosutinib—ABL1—Topotecan—Irinotecan—hematologic cancer	2.41e-05	0.0209	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Epirubicin—hematologic cancer	2.38e-05	0.0206	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Daunorubicin—hematologic cancer	2.34e-05	0.0203	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Daunorubicin—hematologic cancer	2.34e-05	0.0203	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vinorelbine—hematologic cancer	2.26e-05	0.0196	CbGdCrCtD
Bosutinib—PDGFRB—lymph node—hematologic cancer	2.24e-05	0.000604	CbGeAlD
Bosutinib—CYP3A4—hematopoietic system—hematologic cancer	2.2e-05	0.000595	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—hematologic cancer	2.2e-05	0.0191	CbGdCrCtD
Bosutinib—ABL1—lymph node—hematologic cancer	1.99e-05	0.000538	CbGeAlD
Bosutinib—CSK—Menadione—Thalidomide—hematologic cancer	1.99e-05	0.0172	CbGdCrCtD
Bosutinib—CAMK2G—Azacitidine—Fludarabine—hematologic cancer	1.95e-05	0.0169	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Teniposide—hematologic cancer	1.92e-05	0.0166	CbGdCrCtD
Bosutinib—Vandetanib—ALB—hematologic cancer	1.91e-05	0.0124	CrCbGaD
Bosutinib—CAMK2G—Azacitidine—Cytarabine—hematologic cancer	1.84e-05	0.016	CbGdCrCtD
Bosutinib—CAMK2G—Azacitidine—Gemcitabine—hematologic cancer	1.84e-05	0.016	CbGdCrCtD
Bosutinib—Gefitinib—ALB—hematologic cancer	1.81e-05	0.0118	CrCbGaD
Bosutinib—CHEK2—Vindesine—Vincristine—hematologic cancer	1.81e-05	0.0157	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vinblastine—hematologic cancer	1.81e-05	0.0157	CbGdCrCtD
Bosutinib—CAMK2G—Azacitidine—Cladribine—hematologic cancer	1.79e-05	0.0156	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Idarubicin—hematologic cancer	1.77e-05	0.0154	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Idarubicin—hematologic cancer	1.77e-05	0.0154	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Idarubicin—hematologic cancer	1.77e-05	0.0154	CbGdCrCtD
Bosutinib—Gefitinib—ABCB1—hematologic cancer	1.73e-05	0.0113	CrCbGaD
Bosutinib—CHEK2—Doxorubicin—Daunorubicin—hematologic cancer	1.71e-05	0.0148	CbGdCrCtD
Bosutinib—CHEK2—Epirubicin—Daunorubicin—hematologic cancer	1.71e-05	0.0148	CbGdCrCtD
Bosutinib—ERBB3—Podofilox—Etoposide—hematologic cancer	1.69e-05	0.0147	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	1.63e-05	0.0142	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	1.63e-05	0.0142	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	1.63e-05	0.0142	CbGdCrCtD
Bosutinib—ABCB1—hematopoietic system—hematologic cancer	1.56e-05	0.000421	CbGeAlD
Bosutinib—CYP3A4—blood—hematologic cancer	1.46e-05	0.000394	CbGeAlD
Bosutinib—ERBB3—Vinblastine—Vinorelbine—hematologic cancer	1.45e-05	0.0126	CbGdCrCtD
Bosutinib—CHEK2—Epirubicin—Idarubicin—hematologic cancer	1.3e-05	0.0112	CbGdCrCtD
Bosutinib—CHEK2—Doxorubicin—Idarubicin—hematologic cancer	1.3e-05	0.0112	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Idarubicin—hematologic cancer	1.24e-05	0.0107	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	1.24e-05	0.0107	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	1.24e-05	0.0107	CbGdCrCtD
Bosutinib—CHEK2—Vincristine—Vinorelbine—hematologic cancer	1.22e-05	0.0106	CbGdCrCtD
Bosutinib—ABCB1—gonad—hematologic cancer	1.19e-05	0.00032	CbGeAlD
Bosutinib—ERBB3—Vinblastine—Vincristine—hematologic cancer	1.16e-05	0.0101	CbGdCrCtD
Bosutinib—CHEK2—Vinorelbine—Vinblastine—hematologic cancer	1.14e-05	0.00991	CbGdCrCtD
Bosutinib—CHEK2—Vinorelbine—Vincristine—hematologic cancer	1.14e-05	0.00991	CbGdCrCtD
Bosutinib—CHEK2—Teniposide—Etoposide—hematologic cancer	1.14e-05	0.0099	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—hematologic cancer	1.14e-05	0.0099	CbGdCrCtD
Bosutinib—ABCB1—blood—hematologic cancer	1.03e-05	0.000279	CbGeAlD
Bosutinib—ABCB1—bone marrow—hematologic cancer	1e-05	0.00027	CbGeAlD
Bosutinib—CHEK2—Vinblastine—Vinorelbine—hematologic cancer	9.82e-06	0.00852	CbGdCrCtD
Bosutinib—CHEK2—Vincristine—Vinblastine—hematologic cancer	9.76e-06	0.00847	CbGdCrCtD
Bosutinib—ABCB1—lung—hematologic cancer	9.06e-06	0.000245	CbGeAlD
Bosutinib—ABCB1—testis—hematologic cancer	8.55e-06	0.000231	CbGeAlD
Bosutinib—CSK—Doxorubicin—Epirubicin—hematologic cancer	8.13e-06	0.00705	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—hematologic cancer	8.13e-06	0.00705	CbGdCrCtD
Bosutinib—CHEK2—Vinblastine—Vincristine—hematologic cancer	7.85e-06	0.00681	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Dexamethasone—hematologic cancer	7.73e-06	0.00671	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Betamethasone—hematologic cancer	7.73e-06	0.00671	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Triamcinolone—hematologic cancer	7.55e-06	0.00655	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—hematologic cancer	7.52e-06	0.00653	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—hematologic cancer	7.52e-06	0.00653	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Prednisone—hematologic cancer	7.17e-06	0.00622	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Prednisolone—hematologic cancer	7e-06	0.00607	CbGdCrCtD
Bosutinib—Urethral disorder—Epirubicin—hematologic cancer	6.51e-06	0.00011	CcSEcCtD
Bosutinib—Headache—Vincristine—hematologic cancer	6.51e-06	0.00011	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.48e-06	0.000109	CcSEcCtD
Bosutinib—Nausea—Carmustine—hematologic cancer	6.47e-06	0.000109	CcSEcCtD
Bosutinib—Vomiting—Mitoxantrone—hematologic cancer	6.44e-06	0.000108	CcSEcCtD
Bosutinib—Vomiting—Irinotecan—hematologic cancer	6.44e-06	0.000108	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—hematologic cancer	6.41e-06	0.000108	CcSEcCtD
Bosutinib—Nausea—Alitretinoin—hematologic cancer	6.41e-06	0.000108	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—hematologic cancer	6.4e-06	0.000108	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—hematologic cancer	6.39e-06	0.000108	CcSEcCtD
Bosutinib—Rash—Irinotecan—hematologic cancer	6.38e-06	0.000107	CcSEcCtD
Bosutinib—Rash—Mitoxantrone—hematologic cancer	6.38e-06	0.000107	CcSEcCtD
Bosutinib—Dermatitis—Mitoxantrone—hematologic cancer	6.38e-06	0.000107	CcSEcCtD
Bosutinib—Dermatitis—Irinotecan—hematologic cancer	6.38e-06	0.000107	CcSEcCtD
Bosutinib—Headache—Mitoxantrone—hematologic cancer	6.34e-06	0.000107	CcSEcCtD
Bosutinib—Headache—Irinotecan—hematologic cancer	6.34e-06	0.000107	CcSEcCtD
Bosutinib—Nausea—Ifosfamide—hematologic cancer	6.33e-06	0.000107	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.31e-06	0.000106	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.31e-06	0.000106	CcSEcCtD
Bosutinib—Myalgia—Prednisone—hematologic cancer	6.3e-06	0.000106	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—hematologic cancer	6.3e-06	0.000106	CcSEcCtD
Bosutinib—Feeling abnormal—Triamcinolone—hematologic cancer	6.29e-06	0.000106	CcSEcCtD
Bosutinib—Diarrhoea—Cisplatin—hematologic cancer	6.29e-06	0.000106	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—hematologic cancer	6.28e-06	0.000106	CcSEcCtD
Bosutinib—Vomiting—Gemcitabine—hematologic cancer	6.27e-06	0.000105	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.25e-06	0.000105	CcSEcCtD
Bosutinib—Discomfort—Prednisone—hematologic cancer	6.22e-06	0.000105	CcSEcCtD
Bosutinib—Rash—Gemcitabine—hematologic cancer	6.22e-06	0.000105	CcSEcCtD
Bosutinib—Dermatitis—Gemcitabine—hematologic cancer	6.21e-06	0.000105	CcSEcCtD
Bosutinib—ABCB1—lymph node—hematologic cancer	6.2e-06	0.000167	CbGeAlD
Bosutinib—Tinnitus—Epirubicin—hematologic cancer	6.2e-06	0.000104	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—hematologic cancer	6.18e-06	0.000104	CcSEcCtD
Bosutinib—Headache—Gemcitabine—hematologic cancer	6.18e-06	0.000104	CcSEcCtD
Bosutinib—Nausea—Vincristine—hematologic cancer	6.18e-06	0.000104	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—hematologic cancer	6.17e-06	0.000104	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—hematologic cancer	6.15e-06	0.000103	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—hematologic cancer	6.07e-06	0.000102	CcSEcCtD
Bosutinib—Urticaria—Triamcinolone—hematologic cancer	6.07e-06	0.000102	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—hematologic cancer	6.06e-06	0.000102	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—hematologic cancer	6.05e-06	0.000102	CcSEcCtD
Bosutinib—Asthenia—Etoposide—hematologic cancer	6.04e-06	0.000102	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—hematologic cancer	6.04e-06	0.000102	CcSEcCtD
Bosutinib—Body temperature increased—Triamcinolone—hematologic cancer	6.04e-06	0.000102	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—hematologic cancer	6.04e-06	0.000102	CcSEcCtD
Bosutinib—Oedema—Prednisone—hematologic cancer	6.04e-06	0.000102	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—hematologic cancer	6.03e-06	0.000101	CcSEcCtD
Bosutinib—Decreased appetite—Betamethasone—hematologic cancer	6.03e-06	0.000101	CcSEcCtD
Bosutinib—Decreased appetite—Dexamethasone—hematologic cancer	6.03e-06	0.000101	CcSEcCtD
Bosutinib—Nausea—Irinotecan—hematologic cancer	6.01e-06	0.000101	CcSEcCtD
Bosutinib—Nausea—Mitoxantrone—hematologic cancer	6.01e-06	0.000101	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—hematologic cancer	6e-06	0.000101	CcSEcCtD
Bosutinib—Infection—Prednisone—hematologic cancer	6e-06	0.000101	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—hematologic cancer	5.99e-06	0.000101	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.98e-06	0.000101	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.98e-06	0.000101	CcSEcCtD
Bosutinib—Back pain—Methotrexate—hematologic cancer	5.98e-06	0.000101	CcSEcCtD
Bosutinib—Fatigue—Dexamethasone—hematologic cancer	5.98e-06	0.000101	CcSEcCtD
Bosutinib—Fatigue—Betamethasone—hematologic cancer	5.98e-06	0.000101	CcSEcCtD
Bosutinib—Pruritus—Etoposide—hematologic cancer	5.96e-06	0.0001	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—hematologic cancer	5.95e-06	0.00516	CbGdCrCtD
Bosutinib—Pain—Dexamethasone—hematologic cancer	5.93e-06	9.97e-05	CcSEcCtD
Bosutinib—Pain—Betamethasone—hematologic cancer	5.93e-06	9.97e-05	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—hematologic cancer	5.92e-06	9.96e-05	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—hematologic cancer	5.86e-06	9.86e-05	CcSEcCtD
Bosutinib—Nausea—Gemcitabine—hematologic cancer	5.86e-06	9.85e-05	CcSEcCtD
Bosutinib—Vomiting—Cisplatin—hematologic cancer	5.85e-06	9.83e-05	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—hematologic cancer	5.81e-06	9.78e-05	CcSEcCtD
Bosutinib—Rash—Cisplatin—hematologic cancer	5.8e-06	9.75e-05	CcSEcCtD
Bosutinib—Dermatitis—Cisplatin—hematologic cancer	5.79e-06	9.74e-05	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—hematologic cancer	5.78e-06	9.73e-05	CcSEcCtD
Bosutinib—Diarrhoea—Etoposide—hematologic cancer	5.76e-06	9.69e-05	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—hematologic cancer	5.74e-06	9.65e-05	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—hematologic cancer	5.73e-06	9.64e-05	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—hematologic cancer	5.71e-06	9.61e-05	CcSEcCtD
Bosutinib—Feeling abnormal—Dexamethasone—hematologic cancer	5.71e-06	9.61e-05	CcSEcCtD
Bosutinib—Feeling abnormal—Betamethasone—hematologic cancer	5.71e-06	9.61e-05	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—hematologic cancer	5.71e-06	9.6e-05	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—hematologic cancer	5.68e-06	0.00492	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	5.68e-06	0.00492	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	5.68e-06	0.00492	CbGdCrCtD
Bosutinib—Gastrointestinal pain—Betamethasone—hematologic cancer	5.67e-06	9.53e-05	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.67e-06	9.53e-05	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—hematologic cancer	5.66e-06	9.53e-05	CcSEcCtD
Bosutinib—Back pain—Epirubicin—hematologic cancer	5.6e-06	9.41e-05	CcSEcCtD
Bosutinib—Malaise—Methotrexate—hematologic cancer	5.57e-06	9.38e-05	CcSEcCtD
Bosutinib—Dizziness—Etoposide—hematologic cancer	5.57e-06	9.37e-05	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—hematologic cancer	5.55e-06	9.34e-05	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—hematologic cancer	5.54e-06	9.32e-05	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—hematologic cancer	5.53e-06	9.31e-05	CcSEcCtD
Bosutinib—Urticaria—Dexamethasone—hematologic cancer	5.51e-06	9.26e-05	CcSEcCtD
Bosutinib—Urticaria—Betamethasone—hematologic cancer	5.51e-06	9.26e-05	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—hematologic cancer	5.51e-06	0.00478	CbGdCrCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.5e-06	9.25e-05	CcSEcCtD
Bosutinib—Dizziness—Prednisolone—hematologic cancer	5.49e-06	9.24e-05	CcSEcCtD
Bosutinib—Asthenia—Triamcinolone—hematologic cancer	5.48e-06	9.22e-05	CcSEcCtD
Bosutinib—Abdominal pain—Dexamethasone—hematologic cancer	5.48e-06	9.22e-05	CcSEcCtD
Bosutinib—Abdominal pain—Betamethasone—hematologic cancer	5.48e-06	9.22e-05	CcSEcCtD
Bosutinib—Body temperature increased—Betamethasone—hematologic cancer	5.48e-06	9.22e-05	CcSEcCtD
Bosutinib—Body temperature increased—Dexamethasone—hematologic cancer	5.48e-06	9.22e-05	CcSEcCtD
Bosutinib—Nausea—Cisplatin—hematologic cancer	5.46e-06	9.18e-05	CcSEcCtD
Bosutinib—Pruritus—Triamcinolone—hematologic cancer	5.4e-06	9.09e-05	CcSEcCtD
Bosutinib—Cough—Methotrexate—hematologic cancer	5.39e-06	9.07e-05	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—hematologic cancer	5.37e-06	9.03e-05	CcSEcCtD
Bosutinib—Vomiting—Etoposide—hematologic cancer	5.35e-06	9.01e-05	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—hematologic cancer	5.35e-06	9e-05	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—hematologic cancer	5.35e-06	8.99e-05	CcSEcCtD
Bosutinib—Rash—Etoposide—hematologic cancer	5.31e-06	8.93e-05	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—hematologic cancer	5.31e-06	8.92e-05	CcSEcCtD
Bosutinib—Headache—Etoposide—hematologic cancer	5.28e-06	8.87e-05	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—hematologic cancer	5.26e-06	8.85e-05	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—hematologic cancer	5.26e-06	8.85e-05	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—hematologic cancer	5.26e-06	8.85e-05	CcSEcCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	5.25e-06	0.00456	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	5.25e-06	0.00456	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	5.25e-06	0.00456	CbGdCrCtD
Bosutinib—Decreased appetite—Prednisone—hematologic cancer	5.25e-06	8.83e-05	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—hematologic cancer	5.24e-06	8.82e-05	CcSEcCtD
Bosutinib—Rash—Prednisolone—hematologic cancer	5.24e-06	8.81e-05	CcSEcCtD
Bosutinib—Dermatitis—Prednisolone—hematologic cancer	5.23e-06	8.8e-05	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.23e-06	8.79e-05	CcSEcCtD
Bosutinib—Malaise—Epirubicin—hematologic cancer	5.22e-06	8.77e-05	CcSEcCtD
Bosutinib—Fatigue—Prednisone—hematologic cancer	5.2e-06	8.75e-05	CcSEcCtD
Bosutinib—Headache—Prednisolone—hematologic cancer	5.2e-06	8.75e-05	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—hematologic cancer	5.2e-06	8.75e-05	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—hematologic cancer	5.18e-06	8.71e-05	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—hematologic cancer	5.18e-06	8.71e-05	CcSEcCtD
Bosutinib—Dizziness—Triamcinolone—hematologic cancer	5.05e-06	8.5e-05	CcSEcCtD
Bosutinib—Cough—Epirubicin—hematologic cancer	5.05e-06	8.49e-05	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—hematologic cancer	5.04e-06	8.49e-05	CcSEcCtD
Bosutinib—Infection—Methotrexate—hematologic cancer	5.01e-06	8.43e-05	CcSEcCtD
Bosutinib—Nausea—Etoposide—hematologic cancer	5e-06	8.41e-05	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—hematologic cancer	4.97e-06	8.37e-05	CcSEcCtD
Bosutinib—Asthenia—Betamethasone—hematologic cancer	4.97e-06	8.36e-05	CcSEcCtD
Bosutinib—Asthenia—Dexamethasone—hematologic cancer	4.97e-06	8.36e-05	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—hematologic cancer	4.97e-06	8.35e-05	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—hematologic cancer	4.95e-06	8.32e-05	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—hematologic cancer	4.95e-06	8.32e-05	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—hematologic cancer	4.94e-06	8.31e-05	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—hematologic cancer	4.94e-06	8.3e-05	CcSEcCtD
Bosutinib—Nausea—Prednisolone—hematologic cancer	4.93e-06	8.3e-05	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—hematologic cancer	4.92e-06	8.28e-05	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—hematologic cancer	4.92e-06	8.28e-05	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—hematologic cancer	4.92e-06	8.28e-05	CcSEcCtD
Bosutinib—Pruritus—Dexamethasone—hematologic cancer	4.9e-06	8.25e-05	CcSEcCtD
Bosutinib—Pruritus—Betamethasone—hematologic cancer	4.9e-06	8.25e-05	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—hematologic cancer	4.9e-06	8.24e-05	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.89e-06	8.23e-05	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—hematologic cancer	4.87e-06	8.18e-05	CcSEcCtD
Bosutinib—Vomiting—Triamcinolone—hematologic cancer	4.86e-06	8.17e-05	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—hematologic cancer	4.83e-06	8.12e-05	CcSEcCtD
Bosutinib—Rash—Triamcinolone—hematologic cancer	4.82e-06	8.1e-05	CcSEcCtD
Bosutinib—Dermatitis—Triamcinolone—hematologic cancer	4.81e-06	8.09e-05	CcSEcCtD
Bosutinib—Urticaria—Prednisone—hematologic cancer	4.8e-06	8.07e-05	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—hematologic cancer	4.79e-06	8.06e-05	CcSEcCtD
Bosutinib—Headache—Triamcinolone—hematologic cancer	4.79e-06	8.05e-05	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—hematologic cancer	4.77e-06	8.03e-05	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—hematologic cancer	4.77e-06	8.03e-05	CcSEcCtD
Bosutinib—Diarrhoea—Dexamethasone—hematologic cancer	4.74e-06	7.98e-05	CcSEcCtD
Bosutinib—Diarrhoea—Betamethasone—hematologic cancer	4.74e-06	7.98e-05	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—hematologic cancer	4.72e-06	7.94e-05	CcSEcCtD
Bosutinib—Oedema—Epirubicin—hematologic cancer	4.72e-06	7.94e-05	CcSEcCtD
Bosutinib—Infection—Epirubicin—hematologic cancer	4.69e-06	7.89e-05	CcSEcCtD
Bosutinib—Cough—Doxorubicin—hematologic cancer	4.67e-06	7.86e-05	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—hematologic cancer	4.63e-06	7.79e-05	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—hematologic cancer	4.62e-06	7.77e-05	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.6e-06	7.73e-05	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—hematologic cancer	4.59e-06	7.71e-05	CcSEcCtD
Bosutinib—Dizziness—Dexamethasone—hematologic cancer	4.58e-06	7.71e-05	CcSEcCtD
Bosutinib—Dizziness—Betamethasone—hematologic cancer	4.58e-06	7.71e-05	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—hematologic cancer	4.56e-06	7.66e-05	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—hematologic cancer	4.56e-06	7.66e-05	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—hematologic cancer	4.56e-06	7.66e-05	CcSEcCtD
Bosutinib—Nausea—Triamcinolone—hematologic cancer	4.54e-06	7.63e-05	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.53e-06	7.61e-05	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—hematologic cancer	4.5e-06	7.57e-05	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—hematologic cancer	4.5e-06	7.56e-05	CcSEcCtD
Bosutinib—Vomiting—Dexamethasone—hematologic cancer	4.41e-06	7.41e-05	CcSEcCtD
Bosutinib—Vomiting—Betamethasone—hematologic cancer	4.41e-06	7.41e-05	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—hematologic cancer	4.39e-06	7.38e-05	CcSEcCtD
Bosutinib—Rash—Betamethasone—hematologic cancer	4.37e-06	7.35e-05	CcSEcCtD
Bosutinib—Rash—Dexamethasone—hematologic cancer	4.37e-06	7.35e-05	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—hematologic cancer	4.37e-06	7.35e-05	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—hematologic cancer	4.37e-06	7.35e-05	CcSEcCtD
Bosutinib—Dermatitis—Dexamethasone—hematologic cancer	4.37e-06	7.34e-05	CcSEcCtD
Bosutinib—Dermatitis—Betamethasone—hematologic cancer	4.37e-06	7.34e-05	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.36e-06	7.33e-05	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—hematologic cancer	4.35e-06	7.32e-05	CcSEcCtD
Bosutinib—Headache—Dexamethasone—hematologic cancer	4.34e-06	7.3e-05	CcSEcCtD
Bosutinib—Headache—Betamethasone—hematologic cancer	4.34e-06	7.3e-05	CcSEcCtD
Bosutinib—Infection—Doxorubicin—hematologic cancer	4.34e-06	7.3e-05	CcSEcCtD
Bosutinib—Asthenia—Prednisone—hematologic cancer	4.33e-06	7.28e-05	CcSEcCtD
Bosutinib—Pain—Methotrexate—hematologic cancer	4.31e-06	7.26e-05	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.3e-06	7.23e-05	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—hematologic cancer	4.28e-06	7.21e-05	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—hematologic cancer	4.28e-06	7.19e-05	CcSEcCtD
Bosutinib—Pruritus—Prednisone—hematologic cancer	4.27e-06	7.18e-05	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—hematologic cancer	4.24e-06	7.14e-05	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—hematologic cancer	4.21e-06	7.08e-05	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—hematologic cancer	4.16e-06	6.99e-05	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—hematologic cancer	4.13e-06	6.95e-05	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—hematologic cancer	4.13e-06	6.94e-05	CcSEcCtD
Bosutinib—Nausea—Betamethasone—hematologic cancer	4.12e-06	6.92e-05	CcSEcCtD
Bosutinib—Nausea—Dexamethasone—hematologic cancer	4.12e-06	6.92e-05	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—hematologic cancer	4.1e-06	6.9e-05	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.08e-06	6.86e-05	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—hematologic cancer	4.07e-06	6.85e-05	CcSEcCtD
Bosutinib—PKMYT1—Danazol—Prednisone—hematologic cancer	4.07e-06	0.00353	CbGdCrCtD
Bosutinib—Pain—Epirubicin—hematologic cancer	4.04e-06	6.79e-05	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—hematologic cancer	4.01e-06	6.74e-05	CcSEcCtD
Bosutinib—Dizziness—Prednisone—hematologic cancer	3.99e-06	6.71e-05	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—hematologic cancer	3.99e-06	6.71e-05	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—hematologic cancer	3.99e-06	6.71e-05	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.98e-06	6.69e-05	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—hematologic cancer	3.89e-06	6.55e-05	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—hematologic cancer	3.89e-06	6.54e-05	CcSEcCtD
Bosutinib—CSNK1E—Danazol—Prednisone—hematologic cancer	3.88e-06	0.00337	CbGdCrCtD
Bosutinib—Gastrointestinal pain—Epirubicin—hematologic cancer	3.86e-06	6.49e-05	CcSEcCtD
Bosutinib—Vomiting—Prednisone—hematologic cancer	3.84e-06	6.46e-05	CcSEcCtD
Bosutinib—Rash—Prednisone—hematologic cancer	3.81e-06	6.4e-05	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—hematologic cancer	3.8e-06	6.4e-05	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—hematologic cancer	3.8e-06	6.39e-05	CcSEcCtD
Bosutinib—Headache—Prednisone—hematologic cancer	3.78e-06	6.36e-05	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.77e-06	6.34e-05	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—hematologic cancer	3.77e-06	6.33e-05	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—hematologic cancer	3.75e-06	6.31e-05	CcSEcCtD
Bosutinib—Pain—Doxorubicin—hematologic cancer	3.74e-06	6.28e-05	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—hematologic cancer	3.73e-06	6.28e-05	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—hematologic cancer	3.73e-06	6.28e-05	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—hematologic cancer	3.62e-06	6.09e-05	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—hematologic cancer	3.6e-06	6.05e-05	CcSEcCtD
Bosutinib—Nausea—Prednisone—hematologic cancer	3.59e-06	6.03e-05	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.57e-06	6.01e-05	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—hematologic cancer	3.57e-06	6e-05	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—hematologic cancer	3.47e-06	5.84e-05	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—hematologic cancer	3.45e-06	5.81e-05	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—hematologic cancer	3.45e-06	5.81e-05	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—hematologic cancer	3.45e-06	5.81e-05	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—hematologic cancer	3.39e-06	5.7e-05	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—hematologic cancer	3.34e-06	5.62e-05	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—hematologic cancer	3.34e-06	5.61e-05	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—hematologic cancer	3.23e-06	5.43e-05	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—hematologic cancer	3.21e-06	5.39e-05	CcSEcCtD
Bosutinib—Rash—Methotrexate—hematologic cancer	3.18e-06	5.35e-05	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—hematologic cancer	3.18e-06	5.35e-05	CcSEcCtD
Bosutinib—Headache—Methotrexate—hematologic cancer	3.16e-06	5.32e-05	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—hematologic cancer	3.13e-06	5.27e-05	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—hematologic cancer	3.12e-06	5.25e-05	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—hematologic cancer	3.09e-06	5.2e-05	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—hematologic cancer	3e-06	5.05e-05	CcSEcCtD
Bosutinib—Nausea—Methotrexate—hematologic cancer	3e-06	5.04e-05	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—hematologic cancer	2.99e-06	5.03e-05	CcSEcCtD
Bosutinib—Rash—Epirubicin—hematologic cancer	2.98e-06	5.01e-05	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—hematologic cancer	2.97e-06	5e-05	CcSEcCtD
Bosutinib—Headache—Epirubicin—hematologic cancer	2.96e-06	4.97e-05	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—hematologic cancer	2.89e-06	4.86e-05	CcSEcCtD
Bosutinib—Nausea—Epirubicin—hematologic cancer	2.8e-06	4.72e-05	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—hematologic cancer	2.78e-06	4.67e-05	CcSEcCtD
Bosutinib—Rash—Doxorubicin—hematologic cancer	2.75e-06	4.63e-05	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—hematologic cancer	2.75e-06	4.63e-05	CcSEcCtD
Bosutinib—Headache—Doxorubicin—hematologic cancer	2.74e-06	4.6e-05	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Betamethasone—hematologic cancer	2.67e-06	0.00232	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Dexamethasone—hematologic cancer	2.67e-06	0.00232	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Triamcinolone—hematologic cancer	2.61e-06	0.00226	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Triamcinolone—hematologic cancer	2.61e-06	0.00226	CbGdCrCtD
Bosutinib—Nausea—Doxorubicin—hematologic cancer	2.59e-06	4.36e-05	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—hematologic cancer	2.48e-06	0.00215	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—hematologic cancer	2.48e-06	0.00215	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisolone—hematologic cancer	2.42e-06	0.0021	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisolone—hematologic cancer	2.42e-06	0.0021	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Prednisone—hematologic cancer	1.99e-06	0.00172	CbGdCrCtD
Bosutinib—ERBB3—Signaling Pathways—IL6—hematologic cancer	4.84e-08	6.86e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—hematologic cancer	4.84e-08	6.85e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—hematologic cancer	4.83e-08	6.84e-07	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—hematologic cancer	4.83e-08	6.83e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—hematologic cancer	4.81e-08	6.81e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MTOR—hematologic cancer	4.81e-08	6.81e-07	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—hematologic cancer	4.81e-08	6.81e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—hematologic cancer	4.81e-08	6.8e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—hematologic cancer	4.8e-08	6.8e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—hematologic cancer	4.8e-08	6.8e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—hematologic cancer	4.8e-08	6.79e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—hematologic cancer	4.77e-08	6.75e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—hematologic cancer	4.76e-08	6.74e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—hematologic cancer	4.75e-08	6.72e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—hematologic cancer	4.74e-08	6.71e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—hematologic cancer	4.74e-08	6.71e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—hematologic cancer	4.74e-08	6.71e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—hematologic cancer	4.73e-08	6.7e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—hematologic cancer	4.73e-08	6.7e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—hematologic cancer	4.71e-08	6.67e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—hematologic cancer	4.71e-08	6.67e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—hematologic cancer	4.7e-08	6.66e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—hematologic cancer	4.7e-08	6.66e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—hematologic cancer	4.69e-08	6.64e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—hematologic cancer	4.69e-08	6.63e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—hematologic cancer	4.68e-08	6.63e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—hematologic cancer	4.68e-08	6.63e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF2—hematologic cancer	4.68e-08	6.63e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—hematologic cancer	4.67e-08	6.61e-07	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—hematologic cancer	4.66e-08	6.59e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—hematologic cancer	4.64e-08	6.57e-07	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—hematologic cancer	4.63e-08	6.56e-07	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—hematologic cancer	4.63e-08	6.56e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—hematologic cancer	4.63e-08	6.56e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—hematologic cancer	4.63e-08	6.56e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—hematologic cancer	4.63e-08	6.56e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—hematologic cancer	4.62e-08	6.54e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—hematologic cancer	4.62e-08	6.54e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—hematologic cancer	4.62e-08	6.54e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3R1—hematologic cancer	4.62e-08	6.53e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—hematologic cancer	4.61e-08	6.52e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—hematologic cancer	4.59e-08	6.5e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—hematologic cancer	4.59e-08	6.49e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—hematologic cancer	4.58e-08	6.49e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—hematologic cancer	4.56e-08	6.46e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—hematologic cancer	4.56e-08	6.46e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—hematologic cancer	4.55e-08	6.45e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—hematologic cancer	4.54e-08	6.42e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—hematologic cancer	4.54e-08	6.42e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—hematologic cancer	4.54e-08	6.42e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—hematologic cancer	4.53e-08	6.41e-07	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—hematologic cancer	4.52e-08	6.4e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	4.52e-08	6.39e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—hematologic cancer	4.51e-08	6.39e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—hematologic cancer	4.5e-08	6.38e-07	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—hematologic cancer	4.5e-08	6.37e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—hematologic cancer	4.49e-08	6.36e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—hematologic cancer	4.49e-08	6.35e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JAK2—hematologic cancer	4.49e-08	6.35e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—hematologic cancer	4.47e-08	6.33e-07	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—hematologic cancer	4.47e-08	6.32e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—hematologic cancer	4.47e-08	6.32e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—hematologic cancer	4.46e-08	6.32e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—hematologic cancer	4.46e-08	6.31e-07	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—hematologic cancer	4.46e-08	6.31e-07	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—hematologic cancer	4.45e-08	6.3e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—hematologic cancer	4.44e-08	6.29e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—hematologic cancer	4.44e-08	6.29e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—hematologic cancer	4.43e-08	6.27e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—hematologic cancer	4.43e-08	6.27e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—hematologic cancer	4.43e-08	6.27e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—hematologic cancer	4.43e-08	6.27e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—hematologic cancer	4.43e-08	6.27e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—hematologic cancer	4.42e-08	6.26e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—hematologic cancer	4.41e-08	6.25e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—hematologic cancer	4.4e-08	6.24e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—hematologic cancer	4.4e-08	6.23e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—hematologic cancer	4.38e-08	6.2e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—hematologic cancer	4.37e-08	6.19e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—hematologic cancer	4.37e-08	6.19e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—hematologic cancer	4.37e-08	6.19e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—hematologic cancer	4.36e-08	6.17e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—hematologic cancer	4.36e-08	6.17e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—hematologic cancer	4.35e-08	6.15e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—hematologic cancer	4.33e-08	6.14e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—hematologic cancer	4.32e-08	6.12e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—hematologic cancer	4.32e-08	6.11e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—hematologic cancer	4.31e-08	6.1e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—hematologic cancer	4.31e-08	6.1e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—hematologic cancer	4.31e-08	6.1e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—hematologic cancer	4.3e-08	6.09e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—hematologic cancer	4.3e-08	6.08e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—hematologic cancer	4.29e-08	6.07e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—hematologic cancer	4.27e-08	6.04e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—hematologic cancer	4.26e-08	6.04e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MTOR—hematologic cancer	4.26e-08	6.03e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—hematologic cancer	4.26e-08	6.03e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NQO1—hematologic cancer	4.26e-08	6.03e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD44—hematologic cancer	4.26e-08	6.03e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—hematologic cancer	4.25e-08	6.02e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—hematologic cancer	4.24e-08	6.01e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK8—hematologic cancer	4.22e-08	5.98e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—hematologic cancer	4.22e-08	5.97e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—hematologic cancer	4.21e-08	5.96e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—hematologic cancer	4.21e-08	5.96e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—hematologic cancer	4.21e-08	5.95e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—hematologic cancer	4.2e-08	5.94e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—hematologic cancer	4.19e-08	5.93e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—hematologic cancer	4.17e-08	5.9e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	4.17e-08	5.9e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—hematologic cancer	4.16e-08	5.89e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—hematologic cancer	4.15e-08	5.88e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—hematologic cancer	4.15e-08	5.87e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—hematologic cancer	4.14e-08	5.86e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—hematologic cancer	4.13e-08	5.84e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—hematologic cancer	4.12e-08	5.83e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—hematologic cancer	4.12e-08	5.83e-07	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—hematologic cancer	4.11e-08	5.82e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—hematologic cancer	4.09e-08	5.79e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—hematologic cancer	4.08e-08	5.77e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK8—hematologic cancer	4.07e-08	5.76e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—hematologic cancer	4.04e-08	5.71e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—hematologic cancer	4.03e-08	5.71e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYCS—hematologic cancer	4.03e-08	5.71e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—hematologic cancer	4.02e-08	5.69e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—hematologic cancer	4.02e-08	5.69e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—hematologic cancer	4.02e-08	5.69e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4e-08	5.67e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—hematologic cancer	4e-08	5.67e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—hematologic cancer	4e-08	5.66e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—hematologic cancer	3.98e-08	5.63e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—hematologic cancer	3.98e-08	5.63e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—hematologic cancer	3.97e-08	5.61e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—hematologic cancer	3.97e-08	5.61e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.93e-08	5.57e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—hematologic cancer	3.92e-08	5.55e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—hematologic cancer	3.92e-08	5.55e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—hematologic cancer	3.91e-08	5.54e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—hematologic cancer	3.9e-08	5.52e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—hematologic cancer	3.9e-08	5.52e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—hematologic cancer	3.88e-08	5.49e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—hematologic cancer	3.86e-08	5.46e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—hematologic cancer	3.86e-08	5.46e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—hematologic cancer	3.85e-08	5.45e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—hematologic cancer	3.85e-08	5.45e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—hematologic cancer	3.85e-08	5.45e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—hematologic cancer	3.84e-08	5.43e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—hematologic cancer	3.81e-08	5.4e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—hematologic cancer	3.81e-08	5.4e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—hematologic cancer	3.81e-08	5.39e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—hematologic cancer	3.8e-08	5.37e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—hematologic cancer	3.76e-08	5.32e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—hematologic cancer	3.75e-08	5.3e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—hematologic cancer	3.72e-08	5.27e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—hematologic cancer	3.72e-08	5.27e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—hematologic cancer	3.72e-08	5.26e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—hematologic cancer	3.71e-08	5.25e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—hematologic cancer	3.71e-08	5.25e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—hematologic cancer	3.71e-08	5.25e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—hematologic cancer	3.71e-08	5.25e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—hematologic cancer	3.69e-08	5.22e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—hematologic cancer	3.69e-08	5.22e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—hematologic cancer	3.68e-08	5.21e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—hematologic cancer	3.66e-08	5.18e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CREBBP—hematologic cancer	3.65e-08	5.16e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—hematologic cancer	3.62e-08	5.13e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK8—hematologic cancer	3.6e-08	5.1e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—hematologic cancer	3.59e-08	5.08e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—hematologic cancer	3.58e-08	5.07e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—hematologic cancer	3.58e-08	5.06e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—hematologic cancer	3.56e-08	5.04e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—hematologic cancer	3.55e-08	5.03e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.55e-08	5.03e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—hematologic cancer	3.55e-08	5.03e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—hematologic cancer	3.54e-08	5.01e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—hematologic cancer	3.52e-08	4.99e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—hematologic cancer	3.51e-08	4.97e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—hematologic cancer	3.5e-08	4.96e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—hematologic cancer	3.5e-08	4.96e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—hematologic cancer	3.47e-08	4.91e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—hematologic cancer	3.46e-08	4.9e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.46e-08	4.9e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—hematologic cancer	3.46e-08	4.89e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—hematologic cancer	3.45e-08	4.88e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—hematologic cancer	3.43e-08	4.86e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—hematologic cancer	3.42e-08	4.85e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—hematologic cancer	3.41e-08	4.83e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—hematologic cancer	3.41e-08	4.83e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—hematologic cancer	3.39e-08	4.8e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—hematologic cancer	3.38e-08	4.79e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.36e-08	4.76e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—hematologic cancer	3.33e-08	4.71e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—hematologic cancer	3.32e-08	4.7e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—hematologic cancer	3.31e-08	4.69e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—hematologic cancer	3.31e-08	4.69e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—hematologic cancer	3.29e-08	4.66e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—hematologic cancer	3.28e-08	4.65e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—hematologic cancer	3.28e-08	4.65e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—hematologic cancer	3.28e-08	4.65e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.27e-08	4.62e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.26e-08	4.62e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.26e-08	4.62e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—hematologic cancer	3.26e-08	4.62e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—hematologic cancer	3.24e-08	4.59e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—hematologic cancer	3.24e-08	4.58e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—hematologic cancer	3.19e-08	4.52e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—hematologic cancer	3.17e-08	4.49e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—hematologic cancer	3.15e-08	4.45e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—hematologic cancer	3.12e-08	4.42e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—hematologic cancer	3.1e-08	4.39e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—hematologic cancer	3.06e-08	4.33e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—hematologic cancer	3.06e-08	4.33e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—hematologic cancer	3.05e-08	4.32e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—hematologic cancer	3.04e-08	4.31e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—hematologic cancer	3.03e-08	4.29e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	3.01e-08	4.27e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—hematologic cancer	2.99e-08	4.23e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—hematologic cancer	2.94e-08	4.17e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	2.93e-08	4.15e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—hematologic cancer	2.92e-08	4.14e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.88e-08	4.08e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—hematologic cancer	2.88e-08	4.08e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—hematologic cancer	2.86e-08	4.05e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—hematologic cancer	2.84e-08	4.02e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—hematologic cancer	2.83e-08	4e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—hematologic cancer	2.82e-08	3.99e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—hematologic cancer	2.71e-08	3.84e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—hematologic cancer	2.7e-08	3.82e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—hematologic cancer	2.6e-08	3.69e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—hematologic cancer	2.6e-08	3.68e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—hematologic cancer	2.6e-08	3.68e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—hematologic cancer	2.51e-08	3.56e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—hematologic cancer	2.49e-08	3.52e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—hematologic cancer	2.48e-08	3.52e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.42e-08	3.43e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—hematologic cancer	2.4e-08	3.4e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—hematologic cancer	2.4e-08	3.39e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—hematologic cancer	2.3e-08	3.26e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.25e-08	3.18e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.13e-08	3.02e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—hematologic cancer	2.12e-08	3e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—hematologic cancer	2.1e-08	2.98e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.01e-08	2.85e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.86e-08	2.63e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.84e-08	2.6e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—hematologic cancer	1.6e-08	2.27e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—hematologic cancer	1.53e-08	2.17e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—hematologic cancer	1.5e-08	2.13e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.13e-08	1.6e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—hematologic cancer	9.25e-09	1.31e-07	CbGpPWpGaD
